The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...
Zacks Investment Research on MSN6d
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...
Fresenius’s growing pipeline of autoimmune and oncology biosimilars has several molecules in early and late-stage development ...
The FDA has accepted Amneal’s biologics licensing application for two biosimilars referencing Prolia and Xgeva.
The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...
Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt ...
Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous ...
Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline in 2024, with several candidates entering late ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback